NCT07168876Recruiting
Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)
Clinical Validation Cross-sectional Study for Colorectal Cancer Assessment Using Delta-HLD Technology (CLIMBED)
Source: ClinicalTrials.gov · Last updated 11 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3200 (estimated)
- First submitted
- 4 Sept 2025
- Start date
- 4 Apr 2024
- Primary completion date
- Dec 2025
- Lead sponsor
- Epiliquid Holding, Inc
- Diseases
- Colorectal cancer
- NCT number
- NCT07168876
What you commit to
- Study type: Observational
- Planned participants: 3200
- From 4 Apr 2024 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major trauma, surgery, transfusion in past 30 days
Other illness
- First-degree family history of CRC
- Inflammatory bowel disease (ulcerative colitis, Crohn's disease)
- Other malignancies within 5 years
- Known hereditary CRC syndromes (Lynch, FAP)
Other
- Current participation in an interventional clinical trial
Who the study is looking for
- Men and women aged 45-75 years
- Indication of colorectal cancer screening colonoscopy by treating physician
Age in the registry: 45 years to 75 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Epiliquid Coordinator of this site? Confirm its status | Mendoza | Argentina | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.